Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Shares Outstanding (Weighted Average) (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $9.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 5.31% year-over-year to $9.8 million, compared with a TTM value of $9.8 million through Sep 2025, up 5.31%, and an annual FY2024 reading of $9.3 million, up 67.74% over the prior year.
  • Shares Outstanding (Weighted Average) was $9.8 million for Q3 2025 at SAB Biotherapeutics, up from $9.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $43.0 million in Q2 2022 and bottomed at $4.4 million in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $14.9 million, with a median of $9.3 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 993.57% in 2021, then tumbled 88.29% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $27.3 million in 2021, then crashed by 84.08% to $4.4 million in 2022, then grew by 26.86% to $5.5 million in 2023, then surged by 67.74% to $9.3 million in 2024, then rose by 5.28% to $9.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SABS at $9.8 million in Q3 2025, $9.3 million in Q2 2025, and $9.3 million in Q1 2025.